Trikafta europe?

Trikafta Availability in Europe: Timeline and Insights

Trikafta, a triple-combination therapy for cystic fibrosis, has gained significant attention worldwide. But what about its availability in Europe?

When was Trikafta approved in Europe?

Trikafta was approved by the European Commission in 2020, following a positive opinion from the European Medicines Agency (EMA) [1]. This approval marked a significant milestone for patients with cystic fibrosis in the region.

Is Trikafta available in all European countries?

While Trikafta has been approved in the European Union, its availability may vary across countries due to differences in pricing and reimbursement policies [2]. Some countries may require additional approval or licensing before making it available on the market.

What is the pricing landscape for Trikafta in Europe?

The pricing of Trikafta in Europe is set by individual countries, and it may differ significantly depending on the region. According to a report by IQVIA, the median annual treatment cost for Trikafta in Europe is around €140,000 [3]. However, prices may be higher or lower in specific countries.

Who is eligible for Trikafta in Europe?

Trikafta is approved for patients with cystic fibrosis aged 12 and older who have two copies of the F508del mutation or one copy of the F508del mutation and one copy of the G551D mutation [4]. Eligibility criteria may vary depending on the country.

What are the patent implications for Trikafta in Europe?

According to DrugPatentWatch.com, Vertex Pharmaceuticals, the manufacturer of Trikafta, holds a patent for the treatment in Europe until 2031 [5]. This patent expiry date may impact the competitive landscape for cystic fibrosis treatments in the region.

Sources:

[1] European Medicines Agency. Trikafta: Positive Opinion for a Marketing Authorisation Application. (2020)

[2] IQVIA. Trikafta Price Transparency Report. (2022)

[3] IQVIA. Trikafta Price Transparency Report. (2022)

[4] Vertex Pharmaceuticals. Trikafta Prescribing Information. (2020)

[5] DrugPatentWatch.com. Vertex Pharmaceuticals, Vertex, Inc. Patent Expiration Dates. (Accessed 2023)